Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Wegovy

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals.

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3…

‘I lost four stone on Mounjaro – but piled weight back on when I couldn’t afford to keep taking it’

Darren Ratcliffe was paying £270 a month for weight-loss jab Mounjaro

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Evening Standard

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

The Independent UK

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Weight-loss jab Mounjaro helps people shed much more weight than rival – study

Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and therefore less hungry.

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

The Guardian - AU

Weight loss drug Wegovy approved to treat heart disease in overweight and obese Australian patients

TGA approved new indication for semaglutide drug in December 2024, but allocation to PBS still to be decided

The Guardian - UK

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

The Conversation

Considering taking Wegovy to lose weight? Here are the risks and benefits – and how it differs from Ozempic

The weight-loss drug Wegovy is now available in Australia.

The Guardian - UK

Women advised to pair effective contraception with ‘skinny jabs’

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

Decades-old law limits access to Wegovy for Medicaid beneficiaries

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

The Guardian - UK

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

International Business Times

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

Novo Holdings Acquires Catalent for .5 Billion, Expands Wegovy Capacity

Novo Holdings has announced its acquisition of Catalent for .5 billion, a move aimed at expanding the production capacity of Wegovy, a drug used for obe...

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Parkinson Disease

Places

324,930 stories

127,680 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play